We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

This study is currently recruiting participants.
Verified November 2017 by Douglas Johnson, Vanderbilt-Ingram Cancer Center
Sponsor:
ClinicalTrials.gov Identifier:
NCT01205815
First Posted: September 21, 2010
Last Update Posted: November 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Douglas Johnson, Vanderbilt-Ingram Cancer Center
September 17, 2010
September 21, 2010
November 10, 2017
June 3, 2010
January 2020   (Final data collection date for primary outcome measure)
Molecular changes in patients' melanoma tissue [ Time Frame: at 120 months ]
Tissue is collected upon consent or upon receipt of parafin block, primary aim will be met when all tissues are collected and analyzed at conclusion of study. Intent is to aid patients and their treating physician when making treatment decisions.
To determine the molecular changes in the patient's melanoma tissue to aid patients and their treating physician when making treatment decisions [ Time Frame: At baseline ]
Complete list of historical versions of study NCT01205815 on ClinicalTrials.gov Archive Site
Improve the time between ordering the test and results entry into medical records [ Time Frame: 120 months ]
To enhance the speed and detail of molecular mutation profiling of melanoma
Not Provided
Not Provided
Not Provided
 
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
Not Provided
The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.
Not Provided
Observational
Observational Model: Other
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients with melanoma.
Melanoma
Other: Tissue and blood collection
Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
2500
January 2020
January 2020   (Final data collection date for primary outcome measure)

Inclusion criteria

  • Pathologically-proven diagnosis of melanoma.
  • Patient must have a test or procedure that has the potential to provide left-over tissue that can be banked for future research purposes OR the patient has already had a diagnostic or therapeutic procedure but who has not yet been approached to participate is also eligible.

Exclusion criteria

  • Any patient with significant contraindications to venipuncture (e.g., severe anemia) will be excluded from blood collection procedures. However, if the patient provides consent and a paraffin-embedded block or 10-15 unstained slides of their tissue diagnosis, they will not be excluded from this protocol.
  • Any patient unable or unwilling to provide consent.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: VICC Clinical Trials Information Program, RN 800-811-8480
United States
 
 
NCT01205815
VICC MEL 09109
Not Provided
Not Provided
Not Provided
Douglas Johnson, Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
Not Provided
Principal Investigator: Jeffrey Sosman, M.D. Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
November 2017